DCBLD2 is also known to modulate signaling of receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor β (PDGFRβ) in blood vessel development and repair (3, 4, 5), insulin receptor (INSR) in glucose homeostasis (6), and epidermal growth factor receptor (EGFR) in oncogenesis and cancer progression (7, 8). This evidence concerns the gene EGFR and cancer.